FIGURE 5 Antioxidant Treatment Rescues the Aggravated Spiral Ganglion Neurons Loss and Apoptosis Induced by Glutathione Peroxidase 1 Deficiency After Peroxynitrite Injury To explore whether GPX1 plays a protective role in peroxynitrite-induced SGNs damage by reducing intracellular ROS, we conducted a rescue experiment by using the antioxidant N-acetylcysteine (NAC)
Beyond blood sugar management, these hormones also slow gastric emptying, which contributes to increased feelings of fullness and reduced appetite
Yuanye Biotechnology Co., Ltd, Shanghai, China) was dissolved in water (pH 3.0) and stored at 20C
Cardiometabolic benefits: At 48 weeks, improvements included triglyceride reductions up to 40.6% and apoC-III reductions of 38%, along with substantial weight loss (24%) Post-hoc analysis uncovered reductions in albuminuria (3037%) and increased eGFR (8.5 mL/min/1.73 m), suggesting potential kidney-protective effects TRIUMPH-3 and TRIUMPH-OUTCOMES are ongoing Phase 3 studies targeting Cardiovascular safety and outcomes and Renal function in obese individuals with ASCVD or CKD Future with Other GLP-1 and GIP Analogues (Poly-agonists) The development of multi-receptor agonists like retatrutide is the next-generation leap beyond GLP-1 monotherapy, holding potential efficacy comparable to bariatric surgery with fewer GI limitations
Overall wellness Acetyl-L-Carnitine 500 mg
Sarah Armstrong, a member of the AAP guideline committee, stated in a 2023 AAP press briefing: "We do not have the evidence to support pharmacotherapy with GLP-1 agonists below age 12, and clinicians should not extrapolate from adolescent data to younger children without trial-level safety evidence." The Endocrine Society's pediatric obesity guideline similarly restricts pharmacotherapy recommendations to adolescents aged 12 and older when lifestyle interventions have been insufficient [7]
